Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:07 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1320
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 841–852 of 1,320 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
Status at this site: Recruiting
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Recruiting Phase 1 Interventional

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

NCT06447376
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions
Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
Drug
Lead sponsor
Taylor Brooks
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting Phase 2 Interventional

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700
Site status not listed — check the official record
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cleveland Heart and Metabolic Prevention Study

NCT03012022
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure Risk Factors in Healthy Individuals
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT06498960
Site status not listed — check the official record
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CereVasc eShunt System, VP Shunt
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
60 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

NCT02016430
Status at this site: Recruiting
View directory record Official record
Conditions
Dietary Modification, Cardiovascular Risk Factor
Interventions
MeLT Dietary intervention, TLC Dietary intervention, MeLT dietary intervention with TMAO
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiovascular and Metabolic Sciences Biorepository

NCT06560424
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2050
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Recruiting No phase listed Observational

TSC Biosample Repository and Natural History Database

NCT05676099
Status at this site: Recruiting
View directory record Official record
Conditions
Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
Procedure · Genetic · Other
Lead sponsor
National Tuberous Sclerosis Association
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
24
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting Phase 2 Interventional

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

NCT01594723
Site status not listed — check the official record
View directory record Official record
Conditions
Neoplasms, Hematologic
Interventions
120 mg LY2784544
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Recruiting Phase 2 Interventional

A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

NCT05795465
Status at this site: Recruiting
View directory record Official record
Conditions
Respiratory Distress Syndrome, Acute
Interventions
GEn-1124, Placebo
Drug
Lead sponsor
GEn1E Lifesciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting Phase 1 Interventional

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372
Site status not listed — check the official record
View directory record Official record
Conditions
Mesothelioma
Interventions
IAG933
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 2, 2026, 2:07 AM EST
Active, not recruiting Phase 3 Interventional

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290
Site status not listed — check the official record
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Lurbinectedin, Doxorubicin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 2, 2026, 2:07 AM EST

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.